PanoramicaGraficoNotizieSchermataTrader

BVT Bonus Zert GILD 31.12.2024/  DE000VM96JZ2  /

Frankfurt Zert./VONT
08/11/2024  20:04:36 Var.+0.480 Denaro21:59:50 Lettera21:59:50 Sottostante Prezzo di esercizio Expiration date Tipo di opzione
88.180EUR +0.55% -
Quantità in denaro: -		 -
Quantità in lettera: -		 Gilead Sciences Inc - USD 31/12/2024 Call
GlobeNewswire 27/08 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 27/08 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 08/08 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire 08/08 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire 08/08 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire 06/08 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire 05/08 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire 05/08 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
GlobeNewswire 01/08 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 23/07 ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...
GlobeNewswire 15/07 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...
GlobeNewswire 08/07 Memo Therapeutics AG appoints Paul Carter as Chairperson
GlobeNewswire 08/07 Memo Therapeutics AG appoints Paul Carter as Chairperson
GlobeNewswire 04/07 Burns McClellan Mourns the Passing of Founder and CEO, Lisa Burns
GlobeNewswire 01/07 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire 01/07 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire 28/06 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire 26/06 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire 26/06 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
TeleTrader 20/06 US opens mostly higher after labor, housing data
GlobeNewswire 18/06 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire 17/06 Assembly Biosciences Announces $12.6 Million in Equity Financings
GlobeNewswire 10/06 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire 22/05 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire 14/05 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results